ATE396202T1 - Lang wirkendes glucagon-ähnliches peptid-2 für die behandlung von gastrointestinalen krankheiten und störungen - Google Patents

Lang wirkendes glucagon-ähnliches peptid-2 für die behandlung von gastrointestinalen krankheiten und störungen

Info

Publication number
ATE396202T1
ATE396202T1 AT02700079T AT02700079T ATE396202T1 AT E396202 T1 ATE396202 T1 AT E396202T1 AT 02700079 T AT02700079 T AT 02700079T AT 02700079 T AT02700079 T AT 02700079T AT E396202 T1 ATE396202 T1 AT E396202T1
Authority
AT
Austria
Prior art keywords
glucagone
disorders
peptide
treatment
long acting
Prior art date
Application number
AT02700079T
Other languages
English (en)
Inventor
Dominique Bridon
Nissab Boudjellab
Roger Leger
Martin Robitaille
Karen Thibaudeau
Julie Carette
Original Assignee
Conjuchem Biotechnologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Conjuchem Biotechnologies Inc filed Critical Conjuchem Biotechnologies Inc
Application granted granted Critical
Publication of ATE396202T1 publication Critical patent/ATE396202T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT02700079T 2001-02-16 2002-02-15 Lang wirkendes glucagon-ähnliches peptid-2 für die behandlung von gastrointestinalen krankheiten und störungen ATE396202T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26927601P 2001-02-16 2001-02-16

Publications (1)

Publication Number Publication Date
ATE396202T1 true ATE396202T1 (de) 2008-06-15

Family

ID=23026568

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02700079T ATE396202T1 (de) 2001-02-16 2002-02-15 Lang wirkendes glucagon-ähnliches peptid-2 für die behandlung von gastrointestinalen krankheiten und störungen

Country Status (14)

Country Link
US (3) US7112567B2 (de)
EP (2) EP1980572A1 (de)
JP (4) JP4280070B2 (de)
AP (1) AP1886A (de)
AT (1) ATE396202T1 (de)
AU (1) AU2002233089B2 (de)
CA (1) CA2436399A1 (de)
CY (1) CY1108274T1 (de)
DE (1) DE60226702D1 (de)
DK (1) DK1360202T3 (de)
EA (1) EA006160B1 (de)
ES (1) ES2307718T3 (de)
PT (1) PT1360202E (de)
WO (1) WO2002066511A2 (de)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040266673A1 (en) * 2002-07-31 2004-12-30 Peter Bakis Long lasting natriuretic peptide derivatives
US6514500B1 (en) * 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
US20090175821A1 (en) * 1999-05-17 2009-07-09 Bridon Dominique P Modified therapeutic peptides with extended half-lives in vivo
US6887470B1 (en) 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US7601691B2 (en) * 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
BR0010750A (pt) * 1999-05-17 2002-02-26 Conjuchem Inc Peptìdeos insulinotrópicos de longa duração
DK1360202T3 (da) 2001-02-16 2008-09-22 Conjuchem Biotechnologies Inc Langvarigt glucagon-lignende peptid 2 (GLP-2) til behandling af gastrointestinale sygdomme og lidelser
WO2003002136A2 (en) * 2001-06-28 2003-01-09 Novo Nordisk A/S Stable formulation of modified glp-1
WO2004035624A2 (en) * 2002-10-14 2004-04-29 Novo Nordisk A/S Glucagon - like peptide - 2 variants
WO2004085471A2 (en) * 2003-03-24 2004-10-07 Novo Nordisk A/S Glp-2 derivatives
KR101308912B1 (ko) * 2003-06-03 2013-09-23 노보 노르디스크 에이/에스 안정화된 약학적 펩티드 조성물
PL1633391T3 (pl) * 2003-06-03 2012-03-30 Novo Nordisk As Stabilizowane farmaceutycznie kompozycje peptydowe
DK3300721T4 (da) * 2003-11-20 2025-03-03 Novo Nordisk As Propylenglycol-holdige peptidformuleringer hvilke er optimale til fremstilling og til anvendelse i injektionsindretninger
HRP20060362A2 (en) * 2004-04-23 2007-03-31 Conjuchem Biotechnologies Inc. Method for the purification of albumin conjugates
PL1789434T3 (pl) * 2004-08-31 2014-07-31 Novo Nordisk As Zastosowanie tris(hydroksymetylo)aminometanu do stabilizacji peptydów, polipeptydów i białek
EP1809318B1 (de) 2004-11-01 2013-06-12 NPS Pharmaceuticals, Inc. Behandlung von patienten mit kurzdarmsyndrom und dickdarmkontinuität
MX2007005521A (es) * 2004-11-12 2007-05-18 Novo Nordisk As Formulaciones estables de peptidos insulinotropicos.
US8088508B2 (en) 2005-01-31 2012-01-03 Panasonic Corporation Thermal battery
UA95235C2 (en) 2005-05-04 2011-07-25 Зииланд Фарма А/С Glucagon-like-peptide-2 (glp-2) analogues
EA200801174A1 (ru) * 2005-10-24 2009-02-27 Сентокор, Инк. Антитела-миметики glp-2, полипептиды, композиции, способы и применения
US8039432B2 (en) * 2005-11-09 2011-10-18 Conjuchem, Llc Method of treatment of diabetes and/or obesity with reduced nausea side effect
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
JP5290177B2 (ja) * 2006-08-31 2013-09-18 セントカー・インコーポレーテツド Ｇｌｐ−２ミメティボディ、ポリペプチド、組成物、方法および用途
CN101573376B (zh) 2006-11-08 2013-11-06 西兰制药公司 选择性胰高血糖素样肽-2（glp-2）类似物
US20090099074A1 (en) * 2007-01-10 2009-04-16 Conjuchem Biotechnologies Inc. Modulating food intake
US7960336B2 (en) * 2007-08-03 2011-06-14 Pharmain Corporation Composition for long-acting peptide analogs
EP2187929A2 (de) * 2007-09-11 2010-05-26 Mondobiotech Laboratories AG Verwendung eines peptids als therapeutisches mittel
JP2011506442A (ja) * 2007-12-11 2011-03-03 コンジュケム バイオテクノロジーズ インコーポレイテッド インスリン分泌性ペプチド結合体の製剤
CN102131516B (zh) 2008-06-27 2016-03-16 杜克大学 包含弹性蛋白样肽的治疗剂
EP2311486A1 (de) * 2009-10-07 2011-04-20 Nestec S.A. GLP-2 zur Verwendung in der Dünndarm- und Muskelwiederherstellung
EP2314616A1 (de) * 2009-10-23 2011-04-27 Ferring B.V. GLP-2-Peptid-Agonisten
JP5908478B2 (ja) * 2010-08-30 2016-04-26 エヌピーエス ファーマシューティカルズ インコーポレイテッドＮｐｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ｈ「Ｇｌｙ２」ＧＬＰ−２の固相合成
KR101895047B1 (ko) * 2011-12-30 2018-09-06 한미사이언스 주식회사 면역글로불린 단편을 이용한 위치 특이적 글루카곤 유사 펩타이드-2 약물 결합체
CN104540850B (zh) 2012-05-03 2018-05-18 西兰制药公司 胰高血糖素样肽2(glp-2)类似物
AU2013263349B2 (en) 2012-05-17 2016-09-08 Extend Biosciences, Inc Carriers for improved drug delivery
WO2016065042A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
US9616109B2 (en) 2014-10-22 2017-04-11 Extend Biosciences, Inc. Insulin vitamin D conjugates
EP3368556B1 (de) * 2015-10-28 2024-04-10 Tufts University Neuartige polypeptide mit verbesserter proteolytischer stabilität und verfahren zur herstellung und verwendung davon
MY206271A (en) 2016-07-11 2024-12-06 Opko Biologics Ltd Long-acting coagulation factor vii and methods of producing same
EP3551651B1 (de) 2016-12-09 2024-03-06 Zealand Pharma A/S Acylierte glp-1/glp-2 duale agoniste
AU2018223811B2 (en) 2017-02-27 2021-05-27 Urigen N.A. Treatment of lower urinary tract epithelium with glucagon like peptide 2
IL299864B2 (en) 2017-06-16 2024-06-01 Zealand Pharma As Dosage regimes for the administration of glucagon-like-peptide-2 (glp-2) analogues
KR102665710B1 (ko) 2017-08-24 2024-05-14 노보 노르디스크 에이/에스 Glp-1 조성물 및 그 용도
EA202090571A1 (ru) * 2017-09-28 2020-07-30 Ханми Фарм. Ко., Лтд. Конъюгаты производных glp-2 пролонгированного действия
CN108395469A (zh) * 2018-02-01 2018-08-14 滨海吉尔多肽有限公司 一种假脯氨酸二肽的合成方法
WO2020020904A1 (en) 2018-07-23 2020-01-30 Zealand Pharma A/S Therapeutic uses of glp-2 agonists
EP3628683A1 (de) 2018-09-28 2020-04-01 Zealand Pharma A/S Formulierungen von analoga des glucagon-like-peptid-2 (glp-2)
EP3628682A1 (de) 2018-09-28 2020-04-01 Zealand Pharma A/S Formulierungen von analoga des glucagon-like-peptid-2 (glp-2)
CA3129576A1 (en) * 2019-02-11 2020-08-20 Opko Biologics Ltd. Long-acting glp-2 analogs
KR20220150270A (ko) 2019-10-07 2022-11-10 칼리오페, 인크. Gpr119 효능제
JP7761567B2 (ja) 2020-02-18 2025-10-28 ノヴォ ノルディスク アー／エス 医薬製剤
TW202140440A (zh) 2020-02-28 2021-11-01 美商克力歐普股份有限公司 Gpr40激動劑
WO2021236617A1 (en) 2020-05-19 2021-11-25 Kallyope, Inc. Ampk activators
CN116390925A (zh) 2020-06-26 2023-07-04 卡尔优普公司 Ampk活化剂
KR20250075704A (ko) 2022-09-30 2025-05-28 익스텐드 바이오사이언시즈, 인크. 장기-지속형 부갑상선 호르몬

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1160380A (en) * 1966-12-22 1969-08-06 Ford Motor Co Vehicle Engine Arrangement.
US3719667A (en) 1970-08-24 1973-03-06 Lilly Co Eli Epimerization of 6-acylamido and 6-imido penicillin sulfoxide esters
US3840556A (en) 1971-05-28 1974-10-08 Lilly Co Eli Penicillin conversion by halogen electrophiles and anti-bacterials derived thereby
DE3241416A1 (de) * 1982-01-19 1983-07-28 Josef Gartner & Co, 8883 Gundelfingen Isolierverglasung
US4462941A (en) 1982-06-10 1984-07-31 The Regents Of The University Of California Dynorphin amide analogs
DK608589D0 (da) 1989-12-01 1989-12-01 Holm Arne Kemisk fremgangsmaade
US5612034A (en) 1990-10-03 1997-03-18 Redcell, Inc. Super-globuling for in vivo extended lifetimes
US5843440A (en) 1990-10-03 1998-12-01 Redcell Canada, Inc. Cellular and serum protein anchors for modulating pharmacokinetics
AU666853B2 (en) 1991-04-05 1996-02-29 Genentech Inc. Platelet aggregation inhibitors having high specificity for GP IIbIIIa
DE4122210C2 (de) 1991-07-04 1999-04-01 Deutsches Krebsforsch Konjugate aus tumoraktiver Verbindung und Serumalbumin sowie Verfahren zu deren Herstellung und ihre Verwendung
RU95106651A (ru) 1992-06-12 1996-12-27 Де-Тюр Дайнорфин Партнершип (US) Аналоги дзе-тур динорфина и способ лечения толерантных состояний у пациента
EP0602290B1 (de) 1992-12-04 1999-08-25 ConjuChem, Inc. Antikörper-konjugiertes-Hepatitis B-Oberflächenantigen und dessen Verwendung
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US5580853A (en) 1994-03-22 1996-12-03 New England Deaconess Hospital Modified polypeptides with increased biological activity
US5496007A (en) * 1994-05-13 1996-03-05 Reece; Cecil L. Device for holding out-sized documents
WO1996006626A1 (en) 1994-08-26 1996-03-07 Lee Nancy M Analgesic method with dynorphin analogues truncated at the n-terminus
US5990077A (en) 1995-04-14 1999-11-23 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
US6184201B1 (en) * 1995-04-14 2001-02-06 Nps Allelix Corp. Intestinotrophic glucagon-like peptide-2 analogs
US5789379A (en) 1995-04-14 1998-08-04 Allelix Biopharmaceutical Inc. Glucagon-like peptide-2 analogs
US5834428A (en) 1995-04-14 1998-11-10 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
US5654276A (en) 1995-06-07 1997-08-05 Affymax Technologies N.V. Peptides and compounds that bind to the IL-5 receptor
CA2215152A1 (en) 1996-01-12 1997-07-17 Redcell Canada, Inc. Cellular and serum protein anchors for diagnostic imaging
US6277583B1 (en) 1996-02-07 2001-08-21 Conjuchem, Inc. Affinity labeling libraries and applications thereof
WO1997046584A1 (de) 1996-06-05 1997-12-11 Boehringer Mannheim Gmbh Exendin-analoga, verfahren zu deren herstellung und diese enthaltende arzneimittel
US5840733A (en) 1996-07-01 1998-11-24 Redcell, Canada, Inc. Methods and compositions for producing novel conjugates of thrombin inhibitors and endogenous carriers resulting in anti-thrombins with extended lifetimes
US5994500A (en) 1996-07-19 1999-11-30 1149336 Ontario Inc. Antagonists of intestinotrophic GLP-2 peptides
ATE493998T1 (de) 1996-08-08 2011-01-15 Amylin Pharmaceuticals Inc Pharmazeutische zusammensetzung mit einem exendin-4-peptid
EP0929576A1 (de) * 1996-08-30 1999-07-21 Novo Nordisk A/S Glp-2 derivate
WO1998011437A1 (en) 1996-09-16 1998-03-19 Conjuchem, Inc. Affinity labeling libraries with tagged leaving groups
EP1012186B1 (de) * 1996-12-06 2002-07-17 Amgen Inc., Verwendung eines kgf-proteinproduktes und eines glp-2 proteinproduktes für die herstellung eines medikamentes
US5952301A (en) 1996-12-10 1999-09-14 1149336 Ontario Inc. Compositions and methods for enhancing intestinal function
US6723530B1 (en) 1997-02-05 2004-04-20 Amylin Pharmaceuticals, Inc. Polynucleotides encoding proexendin, and methods and uses thereof
US6051557A (en) 1997-05-16 2000-04-18 1149336 Ontario Inc. Methods of enhancing functioning of the upper gastrointestinal tract
ES2293688T5 (es) 1997-08-08 2011-05-04 Amylin Pharmaceuticals, Inc. Nuevos compuestos análogos de la exendina.
ATE235513T1 (de) 1997-11-07 2003-04-15 Conjuchem Inc Opioid-konjugate mit endogenen trägerproteinen
AU1519699A (en) 1997-11-07 1999-05-31 Conjuchem, Inc. Affinity markers for human serum albumin
US6437092B1 (en) 1998-11-06 2002-08-20 Conjuchem, Inc. Conjugates of opioids and endogenous carriers
ES2230727T3 (es) 1997-11-12 2005-05-01 Alza Corporation Procedimiento de administracion dermal de polipeptidos.
ATE383867T1 (de) 1997-11-14 2008-02-15 Amylin Pharmaceuticals Inc Neuartige exendin agonisten
MXPA00004670A (es) 1997-11-14 2003-07-14 Amylin Pharmaceuticals Inc Compuestos agonistas de exendina novedosos.
JP2003522099A (ja) 1998-02-27 2003-07-22 ノボ ノルディスク アクティーゼルスカブ 遅延作用プロファイルを有するｇｌｐ−１のｇｌｐ−１誘導体及びエキセンジン
EP1060192A2 (de) 1998-02-27 2000-12-20 Novo Nordisk A/S Glp-2 derivate mit einem helixgehalt über 25%, die partiell strukturierte mizellenartige aggregate bilden
NZ506839A (en) 1998-03-09 2003-05-30 Zealand Pharma As Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
US6107489A (en) 1998-03-17 2000-08-22 Conjuchem, Inc. Extended lifetimes in vivo renin inhibitors
IL133053A0 (en) 1998-03-23 2001-03-19 Conjuchem Inc Local delivery of long lasting therapeutic agents
US20030170250A1 (en) 1998-03-23 2003-09-11 Ezrin Alan M. Local delivery of long lasting therapeutic agents
US6284725B1 (en) 1998-10-08 2001-09-04 Bionebraska, Inc. Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
US6440417B1 (en) 1998-11-06 2002-08-27 Conjuchem, Inc. Antibodies to argatroban derivatives and their use in therapeutic and diagnostic treatments
US6451974B1 (en) 1999-03-17 2002-09-17 Novo Nordisk A/S Method of acylating peptides and novel acylating agents
US6849714B1 (en) 1999-05-17 2005-02-01 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
EP1179012B2 (de) 1999-05-17 2009-07-15 ConjuChem Biotechnologies Inc. Lang wirkende peptidinhibitoren der virusfusion mit körperzellen bei viralen infektionen
BR0010750A (pt) 1999-05-17 2002-02-26 Conjuchem Inc Peptìdeos insulinotrópicos de longa duração
US7144854B1 (en) 1999-09-10 2006-12-05 Conjuchem, Inc. Long lasting anti-angiogenic peptides
US20040266673A1 (en) 2002-07-31 2004-12-30 Peter Bakis Long lasting natriuretic peptide derivatives
US7601691B2 (en) 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
CA2373680C (en) * 1999-05-17 2008-07-29 Conjuchem Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
JP4209086B2 (ja) 1999-05-17 2009-01-14 コンジュケム バイオテクノロジーズ インコーポレイテッド 長期持続性抗新脈管形成ペプチド
US6514500B1 (en) 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
US6887470B1 (en) 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
DE19926154A1 (de) 1999-06-09 2000-12-14 Ktb Tumorforschungs Gmbh Verfahren zur Herstellung einer injizierbaren Arzneimittelzubereitung
DE19926475A1 (de) 1999-06-10 2000-12-14 Ktb Tumorforschungs Gmbh Träger-Pharmaka-Konjugate
WO2001017568A2 (en) 1999-09-07 2001-03-15 Conjuchem, Inc. Bioconjugation in vivo to pulmonary or blood components
US6706892B1 (en) 1999-09-07 2004-03-16 Conjuchem, Inc. Pulmonary delivery for bioconjugation
US7090851B1 (en) 1999-09-10 2006-08-15 Conjuchem Inc. Long lasting fusion peptide inhibitors of viral infection
DE10012120A1 (de) 2000-03-13 2001-09-27 Ktb Tumorforschungs Gmbh Therapeutische und diagnostische Ligandensysteme mit Transportmolekülbindenden Eigenschaften und diese enthaltende Arzneimittel
BR0206919A (pt) 2001-02-02 2004-07-06 Conjuchem Inc Derivados de fator de liberação de hormÈnio de crescimento de longa duração
DK1360202T3 (da) 2001-02-16 2008-09-22 Conjuchem Biotechnologies Inc Langvarigt glucagon-lignende peptid 2 (GLP-2) til behandling af gastrointestinale sygdomme og lidelser
ATE295370T1 (de) 2001-05-31 2005-05-15 Conjuchem Inc Langwirkende fusionspeptid-inhibitoren für hiv- infektion
US6882816B2 (en) * 2002-02-19 2005-04-19 Matsushita Electric Industrial Co., Ltd. Developing device with developer circulating path
JP2006514607A (ja) 2002-07-31 2006-05-11 コンジュケム，インコーポレーテッド 長時間持続性ナトリウム排泄増加性ペプチド誘導体
DK1648933T3 (da) 2003-07-25 2009-09-07 Conjuchem Biotechnologies Inc Langvarige insulinderivater og fremgangsm der
HRP20060362A2 (en) 2004-04-23 2007-03-31 Conjuchem Biotechnologies Inc. Method for the purification of albumin conjugates
US8039432B2 (en) 2005-11-09 2011-10-18 Conjuchem, Llc Method of treatment of diabetes and/or obesity with reduced nausea side effect
CN101384623B (zh) 2005-12-22 2013-07-24 常山凯捷健生物药物研发（河北）有限公司 白蛋白与治疗剂的预成型偶联物的制备方法

Also Published As

Publication number Publication date
ES2307718T3 (es) 2008-12-01
PT1360202E (pt) 2008-09-01
AU2002233089B2 (en) 2005-12-22
DK1360202T3 (da) 2008-09-22
AP2005003310A0 (en) 2005-06-30
US20060217304A1 (en) 2006-09-28
EA200300857A1 (ru) 2003-12-25
WO2002066511A2 (en) 2002-08-29
US7737251B2 (en) 2010-06-15
EP1980572A1 (de) 2008-10-15
EA006160B1 (ru) 2005-10-27
US7112567B2 (en) 2006-09-26
JP2010150276A (ja) 2010-07-08
JP2009035568A (ja) 2009-02-19
CA2436399A1 (en) 2002-08-29
US20090312259A1 (en) 2009-12-17
JP2004532819A (ja) 2004-10-28
DE60226702D1 (de) 2008-07-03
WO2002066511A3 (en) 2003-03-06
AP1886A (en) 2008-09-20
CY1108274T1 (el) 2014-02-12
EP1360202B1 (de) 2008-05-21
EP1360202A2 (de) 2003-11-12
JP4280070B2 (ja) 2009-06-17
JP2008179652A (ja) 2008-08-07
US20040248782A1 (en) 2004-12-09

Similar Documents

Publication Publication Date Title
DE60226702D1 (de) Lang wirkendes glucagon-ähnliches peptid-2 für die behandlung von gastrointestinalen krankheiten und störungen
DE60218493D1 (de) Substituierte 7-aza-ä2.2.1übicycloheptane für die behandlung von krankheiten
FR13C0060I2 (fr) Omega-carboxyaryldiphenyluree fluoro-subtituee pour le traitement et la prevention de maladies et d'etats pathologiques
ATE374196T1 (de) Dihydrobenzodiazepin-2-on-derivative für die behandlung von neurologischen erkrankungen
DE60329123D1 (de) Benzoädüazepinderivate für die behandlung von neurologischen krankheiten
ATE502642T1 (de) Kombinationen für die behandlung von immun- entzündlichen erkrankungen
ATE439844T1 (de) Kombinationen für die behandlung entzündlicher erkrankungen
PT1446122E (pt) Utilizacao de flibanserina no tratamento de disturbios de desejo sexual
ATE286028T1 (de) Aminopyrazolderivate zur behandlung von übergewicht und anderen gesundheitsstörungen
ATE286895T1 (de) Sulfonyl-pyrrolidinderivate geeignet für die behandlung von neurologischen krankheiten
DE60223715D1 (de) Glyt1 transporter inhibitoren und deren anwendung in der behandlung von neurologischen und neuropsychiatischen krankheiten
DE60216122D1 (de) Cysteinprotease-hemmer mit 2-cyano-4-amino-pyrimidinstruktur und cathepsin-k-hemmender wirkung zur behandlung von entzündungen und anderen erkrankungen
DE60036968D1 (de) Adamantanderivate zur Behandlung von entzündlichen, immunologischen und kardiovaskulären Erkrankungen
DE50214540D1 (de) Stanz bei der behandlung von wunden
DE60204951D1 (de) Ccr5 antagonisten verwendbar für die behandlung von aids
DE60318839D1 (de) 2,6-chinolinyl- und 2,6-naphthylderivate und deren verwendungen zur behandlung von vla-4 bezogenen krankheiten
DE60204466D1 (de) Integrinhemmer zur behandlung von augenkrankheiten
DE60231107D1 (de) Tetrahydro-pyrazinoä1,2-aüindole für die behandlung von krankheiten des zentralnervensystems
DE502004010131D1 (de) Pyridopyrimidinone zur behandlung von krebserkrankungen
DE60236743D1 (de) Zur behandlung androgenabhängiger krankheiten
ATE303379T1 (de) 4-(phenyl-piperidin-4-ylidenmethyl)-benzamid- derivate und deren verwendung zur behandlung von schmerzen, angst oder gastrointestinalen störungen
DE60016047D1 (de) Dihydrobenzopyrane, dihydrobenzothiopyrane und tetrahydrochinoline zur behandlung cox-2-abhängiger krankheiten
EP1377287A4 (de) Proanthocyanidine zur behandlung von amyloid- und alpha-synuclein-krankheiten
ATE443060T1 (de) Benzoägüchinolinderivate zur behandlung von glaucom und kurzsichtigkeit
NO20032156L (no) Behandling av angstforstyrrelser

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1360202

Country of ref document: EP